- Report
- September 2023
- 76 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- June 2023
- 65 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- August 2022
- 54 Pages
Global
From €2338EUR$2,450USD£1,959GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- July 2024
- 90 Pages
India
From €5679EUR$5,950USD£4,758GBP
- Report
- September 2023
- 180 Pages
Global
From €5679EUR$5,950USD£4,758GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more